Nivolumab Monotherapy and Nivolumab Plus Ipilimumab in Recurrent Small Cell Lung Cancer: Results From the CheckMate 032 Randomized Cohort

Journal of Thoracic Oncology - United States
doi 10.1016/j.jtho.2019.10.004
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Elsevier BV

Related search

Third-Line Nivolumab Monotherapy in Recurrent Small Cell Lung Cancer: CheckMate 032

Journal of Thoracic Oncology
MedicineOncologyRespiratory MedicinePulmonary
2019English

Nivolumab Alone and With Ipilimumab in Previously Treated Metastatic Urothelial Carcinoma: CheckMate 032 Nivolumab 1 Mg/Kg Plus Ipilimumab 3 Mg/Kg Expansion Cohort Results

Journal of Clinical Oncology
Cancer ResearchMedicineOncology
2019English

P2.12-16 Significant Tumor Regression and Toxicity With Nivolumab Plus Ipilimumab in Small Cell Lung Cancer Patients Following Radiation

Journal of Thoracic Oncology
MedicineOncologyRespiratory MedicinePulmonary
2018English

Nivolumab in Metastatic Non–Small Cell Lung Cancer

Journal of the Advanced Practitioner in Oncology
2016English

Lambert-Eaton Myasthenic Syndrome Secondary to Nivolumab and Ipilimumab in a Patient With Small-Cell Lung Cancer

Case Reports in Neurological Medicine
2019English

Italian Cohort of Nivolumab Expanded Access Program in Squamous Non‐Small Cell Lung Cancer: Results From a Real‐World Population

Oncologist
Cancer ResearchMedicineOncology
2019English

Pcn184 - Cost-Effectiveness of Nivolumab Plus Ipilimumab in Advanced Melanoma

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2018English

OA10 CheckMate 078: Patient-Reported Outcomes (PROs) With Nivolumab vs Docetaxel in Advanced Non-Small Cell Lung Cancer (NSCLC)

Journal of Thoracic Oncology
MedicineOncologyRespiratory MedicinePulmonary
2018English

P1.01-02 Long-Term Outcomes With First-Line Nivolumab Plus Ipilimumab in Advanced NSCLC: 3-Year Follow-Up From CheckMate 012

Journal of Thoracic Oncology
MedicineOncologyRespiratory MedicinePulmonary
2018English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2025 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy